한빛사 논문
Won-Ju Kim, BSa, b, § , Ja-Hyun Koo, BSa, b, §, Hyun-Jung Cho, MSa, b, Jae-Ung Lee, BSa, b, Ji Yun Kim, MSa, b, Hong-Gyun Lee, BSa, b, Sohee Lee, PhDc, Jong Hoon Kim, MD, PhDd, Mi Seon Oh, BSe, Minah Suh, PhDc, f, g, Eui-Cheol Shin, MD, PhDd, Joo Yeon Ko, MD, PhDh, Myung Hyun Sohn, MD, PhDe, Je-Min Choi, PhDa, b, c,*
a Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea
b Research Institute for Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea
c Center for Neuroscience Imaging Research (CNIR), Institute for Basic Science (IBS), Suwon 16419, Republic of Korea
d Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, KAIST, Daejeon 34141, Republic of Korea
e Department of Pediatrics, Severance Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
f Department of Biomedical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
g Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul 06351, Republic of Korea
h Department of Dermatology, College of Medicine, Hanyang University, Seoul 04763, Republic of Korea
*To whom correspondence should be addressed: Je-Min Choi, PhD Dept. of Life Science, Hanyang University 222 Wangsimni-ro, Seongdong-gu Seoul 04763, Republic of Korea
§ These authors contributed equally to this work.
Abstract
Background
Atopic dermatitis and psoriasis are the two most common chronic inflammatory skin diseases. There is an unmet medical need to overcome limitations for transcutaneous drug development posed by the skin barrier.
Objective
We aimed to identify a novel transdermal delivery peptide and to develop a transcutaneously applicable immunomodulatory protein for treating atopic dermatitis and psoriasis.
Methods
We identified and generated reporter proteins conjugated to AP, a novel transdermal delivery peptide of human origin, and analyzed the intracellular delivery efficiency of these proteins in mouse and human skin cells and tissues using multi-photon confocal microscopy. We also generated a recombinant therapeutic protein, AP-rPTP, consisting of the phosphatase domain of T cell protein tyrosine phosphatase (TC-PTP) conjugated to AP. The immunomodulatory function of AP-rPTP was confirmed in splenocytes upon cytokine stimulation and TcR stimulation. Finally, we confirmed the in vivo efficacy of AP-rPTP transdermal delivery in OXA-induced contact hypersensitivity, OVA-induced atopic dermatitis-like, and imiquimod-induced psoriasis-like skin inflammation models.
Results
AP-conjugated reporter proteins exhibited significant intracellular transduction efficacy in keratinocytes, fibroblasts, and immune cells. In addition, transcutaneous administration of AP-dTomato resulted in showed significant localization into the dermis and epidermis in both mouse and human skin. AP-rPTP inhibited pSTAT1, pSTAT3, and pSTAT6 in splenocytes and also regulated T cell activation and proliferation. Transcutaneous administration of AP-rPTP via the paper-patch technique significantly ameliorated skin tissue thickening, inflammation, and cytokine expression in both atopic dermatitis-like and psoriasis-like dermatitis models.
Conclusion
We identified a 9-amino acid-long novel transdermal delivery peptide, AP, and demonstrated its feasibility for transcutaneous biologic drug development. Moreover, AP-rPTP is a novel immunomodulatory drug candidate for human dermatitis.
Key words : Atopic dermatitis; psoriasis; transdermal delivery peptide; protein tyrosine phosphatase; TC-PTP; transcutaneous drug; immunomodulatory protein
논문정보
TOP52017년 선정
관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기